Replies to post #199627 on Amarin Corp Plc (AMRN)

[ridinbulls]

A+ post! Spot on!

[SonamKapoor]

Yes, Zu - I see it that way too - perhaps what I came away from the NLA in Portland most of all - is that the lipid docs seem to think you need to up prescribe statins to their max before going to secondary therapies. It's like the lipidologists attribute the "residual risk" to not maxing out the statin dose. Hardly any of them are doing that first according to the panelists.

Dr. Peter H. Jones was asked point blank whether he saw a difference between EPA & DHA and he said "NO" adding "not a believer in big difference between EPA & DHA." Remember he's the NLA's "Chief Science Officer" tasked with monitoring and commenting on new developments. If this is the lipidologists' visionary (early adopters), then I don't want to see their pragmatists (mainstream doctors, go along to get along). Laggards will always be (skeptics). So, if AMRN isn't out working the street, then nobody else will for them & lipid doctors will default to statin strategizing.

I think this practice mentality is why JL calls them "statinistas."

EVAPORATE will give AMRN an excuse to sponsor more events in 2020 energized with more "new" CT data (also, new collateral to put into their pitchbook). And that's absolutely right - reps are the ones who set up all these educational events. It's not the NLA or the ACC or the AHA or the ACE or the you name it college of whatever internal medicine specialty setting these symposiums up, meeting with practice groups, etc. It's AMRN's reps - out pounding the pavement.

Good book for those still working & interested is "Crossing the Chasm" by Geoffrey Moore.

[studythosestocks]

Thumbs up Zum

[PacificNW]

Zu,
what would be your personal experience with knowing what you know about reps,
ty

[Whalatane]

Zu. Re Big Bang and Doc’s going all in
Next time when in the Bay Area you’ll have to meet my wife .

In her dept at the largest hospital here , they never see a rep .
Instead head of dept goes to conference .. watch’s a presentation by some one like Dr Bhatt ... comes back and tells the staff .. OK starting writing scripts for this drug for this patient profile .

So she scans the profile of the 120 or more CKD patients she writes up each month ... and writes scripts for those that fit the profile

All without seeing a rep

Not to say reps don’t have a roll but in my wife’s experience it’s the KOL’s presentation at key conferences that really matter ...

I expect Dr Bhatt to be very busy spreading the word , this year .

Amarins PR today tells me that they are seeing great trends developing and are preparing to aggressively expand sales once the expanded indication is approved .

They will hit the ground running
JMO
Kiwi

[ziploc_1]

Zu:...From my personal experiences with reps:


1.the rep tries to become personally acquainted with the Doc's staff in order to gain access to Doc…sometimes doing them favors, including office dinners for the Doc and his staff
2. rep tries to establish a personal relationship with the Doc.
3. rep details Doc on product, including leaving reprints of pertinent articles and samples of the product.
4. rep arranges KOL meetings and dinners...at which he is present and he tries to extend his personal relationship with Doc.

This takes several visits